Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Cyclophosphamide
Drug: Capecitabine
Drug: Methotrexate

First Posted Date: 2005-07-21

Last Posted Date: 2013-12-24

Lead Sponsor: Harold J. Burstein, MD, PhD

Target Recruit Count: 164

Registration Number: NCT00121134

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Phase 3

Completed

Conditions: Breast Neoplasms

Interventions: Drug: 5-fluorouracil
Drug: Docetaxel
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2005-07-21

Last Posted Date: 2023-04-04

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 1060

Registration Number: NCT00121992

Locations: 🇪🇸
Spanish Breast Cancer Research Group, San Sebastián de los Reyes, Madrid, Spain

Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma

Interventions: Biological: rituximab
Biological: bevacizumab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2005-07-21

Last Posted Date: 2014-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 73

Registration Number: NCT00121199

Locations: 🇺🇸
SWOG, Portland, Oregon, United States

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Phase 2

Completed

Conditions: Male Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer

Interventions: Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: bevacizumab
Drug: paclitaxel
Biological: filgrastim
Biological: pegfilgrastim
Radiation: radiation therapy
Drug: tamoxifen citrate
Drug: aromatase inhibition therapy

First Posted Date: 2005-07-13

Last Posted Date: 2014-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 226

Registration Number: NCT00119262

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: incomplete Freund's adjuvant
Biological: melanoma helper peptide vaccine
Biological: multi-epitope melanoma peptide vaccine
Biological: tetanus toxoid helper peptide
Drug: cyclophosphamide

First Posted Date: 2005-07-11

Last Posted Date: 2021-04-20

Lead Sponsor: Craig L Slingluff, Jr

Target Recruit Count: 170

Registration Number: NCT00118274

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Large B Cell Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin
Drug: vincristine
Drug: prednisone
Drug: filgrastim
Drug: etoposide
Drug: pegfilgrastim

First Posted Date: 2005-07-11

Last Posted Date: 2021-11-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 524

Registration Number: NCT00118209

Locations: 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸
Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States
🇺🇸
Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States

and more 44 locations

Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

Phase 3

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Cyclophosphamide
Radiation: Radiotherapy
Drug: Vincristine
Drug: Prednisolone
Drug: Rituximab

First Posted Date: 2005-06-24

Last Posted Date: 2022-11-18

Lead Sponsor: Trans Tasman Radiation Oncology Group

Target Recruit Count: 150

Registration Number: NCT00115700

Locations: 🇳🇿
Wellington Hospital, Wellington, New Zealand
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
The Canberra Hospital, Garran, Australian Capital Territory, Australia

and more 18 locations

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

Phase 2

Completed

Conditions: Breast Cancer
Fever
Neutropenia

First Posted Date: 2005-06-23

Last Posted Date: 2008-08-01

Lead Sponsor: Amgen

Registration Number: NCT00115414

Scleroderma: Cyclophosphamide or Transplantation

Phase 2

Completed

Conditions: Scleroderma, Systemic
Autoimmune Disease
Sclerosis

Interventions: Biological: mHSCT
Drug: cyclophosphamide

First Posted Date: 2005-06-16

Last Posted Date: 2023-04-12

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT00114530

Locations: 🇺🇸
University of Toledo Health Science Campus, Toledo, Ohio, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇨🇦
University of Calgary, Calgary, Alberta, Canada

and more 14 locations

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Phase 1

Completed

Conditions: Smoldering Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Stage I Multiple Myeloma
Refractory Multiple Myeloma

Interventions: Radiation: total marrow irradiation
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Biological: filgrastim
Genetic: fluorescence in situ hybridization
Genetic: cytogenetic analysis
Drug: cyclophosphamide
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Drug: lenalidomide

First Posted Date: 2005-06-03

Last Posted Date: 2021-03-01

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 54

Registration Number: NCT00112827

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy